Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

The treatment landscape for high-risk, BCG-unresponsive non–muscle-invasive bladder cancer has expanded significantly, with 3 FDA-approved bladder-sparing therapies now available: pembrolizumab, ...

The Novel Tracer 89Zr-TLX250 Main Discussion Topics: 89Zr-TLX250 is an antibody that binds to carbonic anhydrase IX (CAIX). CAIX is an enzyme expressed on the surface of most clear cell renal cell ...

Key Takeaways Zanzalintinib and nivolumab showed a 63% response rate and 18.5-month median PFS in stage 4 RCC. The study included patients with advanced RCC, treated with zanzalintinib plus nivolumab ...

In this episode of Pearls and Perspectives, host Amy Pearlman, MD, is joined by Joshua R. Gonzalez, MD —a board-certified urologist and sexual medicine specialist based in Los Angeles, California—for ...

Diagnostic Performance of the ZIRCON Trial Main Discussion Topics: A 93% to 95% positive predictive value for clear cell renal cell carcinoma (ccRCC) A 75% negative predictive value Important ...

The cornerstone for first-line treatment in metastatic prostate cancer is androgen deprivation therapy (ADT), although there are several other options that can be used to personalize treatment to the ...

Bedke explained, “I think the important message is that we have no specific subgroup which will have a more pronounced benefit of EV+P if compared to the platinum-based chemotherapy. Selecting ...

Physician Summary: Overcoming Challenges in Accessing New Therapies for NMIBC Access to new therapies for non-muscle invasive bladder cancer (NMIBC) presents several challenges, including cost, ...

Key Takeaways Apalutamide showed a significant survival advantage over abiraterone and enzalutamide in mCSPC, with a 26% and 23% reduction in mortality risk, respectively. Real-world data are ...

Key Takeaways The FDA authorized an Expanded Access Program for NAI to manage lymphopenia in refractory or relapsed solid tumor patients. ImmunityBio’s Cancer BioShield platform enhances NK and T cell ...

Key Takeaways Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, ...